OPTIMIZE IDE for the Treatment of ACS

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1630 participants.

Also called NCT03190473

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,630 participants (enrolled count) (from the registry)
Sponsor
Svelte Medical Systems, Inc. (from the registry)
Registry
  • NCT NCT03190473
Other papers using this trial's data
  • Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study Circulation. Cardiovascular interventions, 2021-09 DOI, PubMed 34353122

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Japan, Netherlands (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03190473. Randomized; single masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2020-07-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
OPTIMIZE IDE for the Treatment of ACS
Acronym
OPTIMIZE
Condition
Acute Coronary Syndrome
Intervention (Device)
DES
Lead sponsor
Svelte Medical Systems, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03190473
Content hash
dc7bb9db9ac6fe933b5e30d16a200765cda4c425257ed771acaa2dd7a88df753